Corbus appoints Brent Pfeiffenberger to board; shareholders approve 3M share increase for equity plan

Corbus Pharmaceuticals Holdings, Inc.

Appointed Brent Pfeiffenberger (CEO Century Therapeutics, former SVP BMS) to board, expanding to 7 members.
Stockholders approved amendment to 2024 Equity Plan increasing authorized shares by 3M to total 5M shares.
All six director nominees elected; advisory say-on-pay approved with 92% of votes cast in favor.
CRB-701 Nectin-4 ADC data at ASCO 2026; FDA alignment on registration path for HNSCC; registrational study this summer.
CANYON-1 Phase 1b study for CRB-913 (CB1 inverse agonist) on track to complete summer 2026.

item 5.02 item 5.07 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brent Pfeiffenberger

Director

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Effective: 2026-05-13
Filed: May 14, 2026, 8:15 AM ET

On May 13, 2026, the board of directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brent Pfeiffenberger was appointed as director at Corbus Pharmaceuticals Holdings, Inc..

Action: appointed

Exact text from the filing

On May 13, 2026, the board of directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members.

View on SEC.gov

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-222890

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.